Mae ivacaftor (Kalydeco) yn feddyginiaeth newydd ar gyfer trin cleifion â ffibrosis systig a’r mwtaniad G551D yn y genyn CFTR. Mae ar gael i gleifion yn Lloegr ond nid yw’r Sefydliad Cenedlaethol dros Ragoriaeth mewn Iechyd a Gofal (NICE) wedi’i arfarnu. Cafodd ei arfarnu gan Gonsortiwm Meddyginiaethau’r Alban (SMC) ac ni argymhellwyd ei ddefnyddio. Ers hynny mae’r feddyginiaeth wedi’i hariannu drwy system newydd a sefydlwyd gan Lywodraeth yr Alban mewn ymateb i feddyginiaethau amddifad.
Ivacaftor (Kalydeco) is a new medicine for the treatment of patients with cystic fibrosis and the G551D  mutation in the CFTR gene.   It has been made available to patients in England although it has not been appraised by the National Institute for Health and Care Excellence (NICE).  In Scotland it was appraised by the Scottish Medicines Consortium (SMC) and  was not recommended for use. It has been subsequently funded by a new mechanism set up by the Scottish Government to respond to orphan medicines.